FDA Movement on Acomplia

The FDA's Endocrinologic and Metabolic Drugs Advisory Committee, which reviews and evaluates data concerning the safety and effectiveness of investigational drugs for use in the treatment of endocrine and metabolic disorders, now has its next meeting tentatively scheduled for January 23rd.

It is not clear whether FDA will discuss about the new anti-obesity drug Acomplia (rimonabant). The developer of a drug, Sanofi-Aventis in the case of Acomplia, would need to be invited to attend 60 days in advance of any meeting where the drug was to be discussed, and there has been no word as to whether it has been invited to the Jan. 23rd committee meeting.

On January 23rd FDA Committee will have joint meeting with the Nonprescription Drugs Advisory Committee, If the Endocrinologic and Metabolic Drugs Advisory Committee does not consider Acomplia in January, its next meeting to be scheduled in starting March.

nfeeds.com